To test the hypothesis that KDM5A may be an upstream regulator of IBM pathology, we next investigated if its inhibition would modulate hallmark pathological features (p62 and APP aggregation) in a previously established IBM‐mimicking cellular model. The gene discussed is SQSTM1; the disease is inclusion body myositis.